- This event has passed.
Cycle 2: Alzheimer’s Drug Discovery Foundation
May 20, 2022
CYCLE 2 Deadlines
- Letter of Intent: May 20, 2022
- Full Proposal: July 22, 2022
Drug Discovery Program
Seeks to fund promising preclinical drug discovery and biomarker development programs for Alzheimer’s disease, related dementias and cognitive aging. The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 for a preclinical project depending on the stage of research and must be justified based on the scientific work plan. In some cases, multi-year proposals can be considered.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use. One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.